EverSource Wealth Advisors LLC Raises Position in Zoetis Inc. (NYSE:ZTS)

EverSource Wealth Advisors LLC boosted its stake in Zoetis Inc. (NYSE:ZTSGet Rating) by 66.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 342 shares of the company’s stock after buying an additional 137 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Zoetis were worth $65,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Horizon Investments LLC increased its stake in shares of Zoetis by 5.5% during the fourth quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after purchasing an additional 477 shares in the last quarter. Resources Management Corp CT ADV increased its stake in shares of Zoetis by 18.7% during the first quarter. Resources Management Corp CT ADV now owns 3,112 shares of the company’s stock valued at $587,000 after purchasing an additional 491 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Zoetis by 4.5% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 151,858 shares of the company’s stock valued at $28,643,000 after purchasing an additional 6,593 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Zoetis by 6.3% during the first quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company’s stock valued at $217,000 after purchasing an additional 68 shares in the last quarter. Finally, Elk River Wealth Management LLC increased its stake in shares of Zoetis by 22.6% during the first quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company’s stock valued at $5,784,000 after purchasing an additional 5,651 shares in the last quarter. Institutional investors own 91.05% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 4,334 shares of the company’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Roxanne Lagano sold 4,334 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,145,225. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,501 shares of company stock worth $2,949,073. Insiders own 0.12% of the company’s stock.

Zoetis Stock Down 1.2 %

ZTS opened at $157.30 on Friday. The stock has a market cap of $73.64 billion, a price-to-earnings ratio of 35.67, a price-to-earnings-growth ratio of 2.78 and a beta of 0.77. Zoetis Inc. has a fifty-two week low of $154.18 and a fifty-two week high of $249.27. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. The firm’s fifty day moving average is $169.18 and its 200 day moving average is $174.69.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.19 earnings per share. On average, sell-side analysts forecast that Zoetis Inc. will post 5.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ZTS shares. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. The Goldman Sachs Group reduced their price target on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a research report on Thursday, July 21st. Stifel Nicolaus reduced their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. StockNews.com raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 9th. Finally, Piper Sandler started coverage on shares of Zoetis in a research report on Monday, July 11th. They set an “overweight” rating and a $205.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $224.00.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.